We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA announced the first biosimilar of Roche’s blockbuster cancer drug Rituxan (rituximab) — approving Teva and Celltrion’s Truxima (rituximab-abbs) for treating non-Hodgkin’s lymphoma. Read More
Dupixent was previously shot down in April by the UK’s National Institute for Health Care and Excellence over concerns about the drug’s cost-effectiveness. Read More